Skip to Content

Rayos Approval History

FDA Approved: Yes (First approved July 26, 2012)
Brand name: Rayos
Generic name: prednisone
Dosage form: Delayed-Release Tablets
Previous Name: Lodotra
Company: Horizon Pharma, Inc.
Treatment for: Rheumatoid Arthritis, Polymyalgia Rheumatica, Psoriatic Arthritis, Ankylosing Spondylitis, Asthma, COPD

Rayos (prednisone) is a delayed release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases including rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma and chronic obstructive pulmonary disease (COPD).

Development History and FDA Approval Process for Rayos

DateArticle
Jul 27, 2012Approval Horizon Pharma Announces FDA Approval of Rayos (prednisone) Delayed-Release Tablets for Rheumatoid Arthritis and Multiple Additional Indications
Sep 24, 2007Nitec's IND Application for Clinical Development With LodotraAccepted by the FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide